Polyplus is a biotechnology company specializing in the development, marketing, and sale of advanced solutions for the delivery of nucleic acids. The company serves clients in the research, bioproduction, and therapeutic sectors, providing essential tools for gene and cell therapy production. Operating in the global biotechnology market, Polyplus offers a range of products including transfection reagents, kits, and support services. In 2022, the company expanded its portfolio to include custom plasmid vector design, aiming to optimize process economics while adhering to stringent scientific and regulatory standards. Polyplus generates revenue through the sale of its innovative products and services, catering to both academic and commercial clients engaged in proof-of-concept studies, preclinical studies, and clinical trials. The company is committed to reliability, safety, and cost-effectiveness in nucleic acid-based therapies.

Keywords: biotechnology, nucleic acid delivery, transfection reagents, gene therapy, cell therapy, bioproduction, custom plasmid vectors, research, clinical trials, regulatory standards.